Loading
A phase 2 trial of Sepantronium Bromide in non-Hodgkin lymphoma, burkitt lymphoma and diffuse large B-cell lymphoma, run by Cothera Bioscience, Inc, active and no longer recruiting.
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma is a phase 2 interventional study registered as NCT05263583 by Cothera Bioscience, Inc, with 14 participants enrolled, started 2022-12-09 and due to reach its primary completion in 2025-03-01. Interventions recorded: Sepantronium Bromide.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.